These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 11092464)

  • 1. Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.
    Terpos E; Palermos J; Tsionos K; Anargyrou K; Viniou N; Papassavas P; Meletis J; Yataganas X
    Eur J Haematol; 2000 Nov; 65(5):331-6. PubMed ID: 11092464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment.
    Terpos E; Palermos J; Viniou N; Vaiopoulos G; Meletis J; Yataganas X
    Calcif Tissue Int; 2001 May; 68(5):285-90. PubMed ID: 11683535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma.
    Terpos E; Viniou N; de la Fuente J; Meletis J; Voskaridou E; Karkantaris C; Vaiopoulos G; Palermos J; Yataganas X; Goldman JM; Rahemtulla A
    Eur J Haematol; 2003 Jan; 70(1):34-42. PubMed ID: 12631257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Parente R; Cangini D; Tacchetti P; Perrone G; Ceccolini M; Boni P; Tura S; Baccarani M; Cavo M
    Eur J Haematol; 2006 May; 76(5):399-404. PubMed ID: 16480429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
    Patel CG; Yee AJ; Scullen TA; Nemani N; Santo L; Richardson PG; Laubach JP; Ghobrial IM; Schlossman RL; Munshi NC; Anderson KC; Raje NS
    Clin Cancer Res; 2014 Aug; 20(15):3955-61. PubMed ID: 24958808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients.
    Alexandrakis MG; Passam FH; Malliaraki N; Katachanakis C; Kyriakou DS; Margioris AN
    Clin Chim Acta; 2002 Nov; 325(1-2):51-7. PubMed ID: 12367766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
    Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
    J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy.
    Kraj M; Pogłód R; Pawlikowski J; Maj S; Nasiłowska B
    Acta Pol Pharm; 2000 Nov; 57 Suppl():113-6. PubMed ID: 11293237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
    Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
    Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover.
    Rosen HN; Dresner-Pollak R; Moses AC; Rosenblatt M; Zeind AJ; Clemens JD; Greenspan SL
    Calcif Tissue Int; 1994 Jan; 54(1):26-9. PubMed ID: 8118749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical markers of bone metabolism reflect osteoclastic and osteoblastic activity in multiple myeloma.
    Abildgaard N; Glerup H; Rungby J; Bendix-Hansen K; Kassem M; Brixen K; Heickendorff L; Nielsen JL; Eriksen EF
    Eur J Haematol; 2000 Feb; 64(2):121-9. PubMed ID: 10997332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined calcitriol-pamidronate therapy for bone hyperresorption in spinal cord injury.
    Chen B; Mechanick JI; Nierman DM; Stein A
    J Spinal Cord Med; 2001; 24(4):235-40. PubMed ID: 11944781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma.
    Abildgaard N; Rungby J; Glerup H; Brixen K; Kassem M; Brincker H; Heickendorff L; Eriksen EF; Nielsen JL
    Eur J Haematol; 1998 Aug; 61(2):128-34. PubMed ID: 9714526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markers of bone resorption in patients treated with pamidronate.
    Lipton A; Demers L; Curley E; Chinchilli V; Gaydos L; Hortobagyi G; Theriault R; Clemens D; Costa L; Seaman J; Knight R
    Eur J Cancer; 1998 Dec; 34(13):2021-6. PubMed ID: 10070304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.
    Berenson JR; Lichtenstein A; Porter L; Dimopoulos MA; Bordoni R; George S; Lipton A; Keller A; Ballester O; Kovacs MJ; Blacklock HA; Bell R; Simeone J; Reitsma DJ; Heffernan M; Seaman J; Knight RD
    N Engl J Med; 1996 Feb; 334(8):488-93. PubMed ID: 8559201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia.
    Voskaridou E; Terpos E; Spina G; Palermos J; Rahemtulla A; Loutradi A; Loukopoulos D
    Br J Haematol; 2003 Nov; 123(4):730-7. PubMed ID: 14616979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.